Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 10 Mar 2017
Price : $35 *
At a glance
- Drugs Empegfilgrastim (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Registrational; Therapeutic Use
- Sponsors Biocad
- 31 Aug 2016 Status changed from active, no longer recruiting to completed.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Primary endpoint has been met (treatment failure) as result presented 51st Annual Meeting of the American Society of Clinical Oncology.